Literature DB >> 10715254

Aspirin use is low among United States outpatients with coronary artery disease.

R S Stafford1.   

Abstract

BACKGROUND: The goal of the present study was to assess national trends and patterns of aspirin use among outpatients with coronary artery disease. Although there is strong evidence that the use of aspirin reduces the risk of death and recurrent events in patients with coronary artery disease, current national patterns of aspirin use are unknown. METHODS AND
RESULTS: We used data from the 1980 to 1996 National Ambulatory Medical Care Surveys. These surveys provide a nationally representative sample of physician activities during patient visits to physician offices. We evaluated the report of aspirin as a new or continuing medication in 10 942 visits to cardiologists and primary care physicians by patients with coronary artery disease. We evaluated trends in the use of aspirin for 1980 to 1996 and used logistic regression to identify independent predictors of aspirin use for 1993 to 1996. Aspirin use in outpatient visits by persons with coronary artery disease without reported contraindications increased from 5.0% in 1980 to 26.2% in 1996. Large increases occurred in the early 1990s. Independent predictors of aspirin use in 1993 to 1996 were male patient gender (29% versus 21% for females), patient age of <80 years (28% versus 17% for age of >/=80 years), and presence of hyperlipidemia (45% versus 24% for patients without hyperlipidemia; all comparisons P<0. 001). Cardiologists (37%) were more likely to report aspirin use than were internists (20%), family physicians (18%), or general practitioners (11%; P<0.001). These effects persisted after we controlled for potential confounders with the use of logistic regression.
CONCLUSIONS: Although aspirin use in patients with coronary artery disease has increased dramatically, it remains suboptimum. Low rates of aspirin use and variations in use suggest a need to better translate clinical recommendations into practice.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10715254     DOI: 10.1161/01.cir.101.10.1097

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  17 in total

1.  Antithrombotic pharmacotherapy in the elderly: general issues and clinical conundrums.

Authors:  Davide Capodanno; Dominick J Angiolillo
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-02

2.  Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000-2010.

Authors:  Matthew Daubresse; Hsien-Yen Chang; Yuping Yu; Shilpa Viswanathan; Nilay D Shah; Randall S Stafford; Stefan P Kruszewski; G Caleb Alexander
Journal:  Med Care       Date:  2013-10       Impact factor: 2.983

3.  Confirmation of reported aspirin use in community studies: utility of serum thromboxane B2 measurement.

Authors:  Nicole Dodge Zantek; Russell V Luepker; Sue Duval; Karen Miller; Niki Oldenburg; Alan T Hirsch
Journal:  Clin Appl Thromb Hemost       Date:  2013-05-07       Impact factor: 2.389

4.  Aspirin use and cardiovascular events in social networks.

Authors:  Kate W Strully; James H Fowler; Joanne M Murabito; Emelia J Benjamin; Daniel Levy; Nicholas A Christakis
Journal:  Soc Sci Med       Date:  2012-02-04       Impact factor: 4.634

5.  Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.

Authors: 
Journal:  BMJ       Date:  2002-01-12

6.  Comparison of the racial/ethnic prevalence of regular aspirin use for the primary prevention of coronary heart disease from the multi-ethnic study of atherosclerosis.

Authors:  Daniel R Sanchez; Ana V Diez Roux; Erin D Michos; Roger S Blumenthal; Pamela J Schreiner; Gregory L Burke; Karol Watson
Journal:  Am J Cardiol       Date:  2011-01       Impact factor: 2.778

7.  Aspirin use post-acute coronary syndromes: intolerance, bleeding and discontinuation.

Authors:  L Kristin Newby; Manjushri V Bhapkar; Harvey D White; David J Moliterno; Nancy M Allen LaPointe; David E Kandzari; Freek W A Verheugt; Judith M Kramer; Paul W Armstrong; Robert M Califf
Journal:  J Thromb Thrombolysis       Date:  2003-12       Impact factor: 2.300

Review 8.  Women and ischemic heart disease: evolving knowledge.

Authors:  Leslee J Shaw; Raffaelle Bugiardini; C Noel Bairey Merz
Journal:  J Am Coll Cardiol       Date:  2009-10-20       Impact factor: 24.094

Review 9.  Aspirin for the prevention of cardiovascular events in the elderly.

Authors:  Isabelle Mahé; Alain Leizorovicz; Charles Caulin; Jean-François Bergmann
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

Review 10.  Factors influencing the decline in stroke mortality: a statement from the American Heart Association/American Stroke Association.

Authors:  Daniel T Lackland; Edward J Roccella; Anne F Deutsch; Myriam Fornage; Mary G George; George Howard; Brett M Kissela; Steven J Kittner; Judith H Lichtman; Lynda D Lisabeth; Lee H Schwamm; Eric E Smith; Amytis Towfighi
Journal:  Stroke       Date:  2013-12-05       Impact factor: 7.914

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.